Related Experiment Videos
Identification and development of new biopharmaceuticals
1Boehringer Ingelheim Pharma KG, Biberach an der Riss, Germany.
Arzneimittel-Forschung
|June 25, 1998
Summary
Biopharmaceuticals show efficacy but face economic competition. Future therapies like gene therapy and oligonucleotide antisense therapy, supported by the human genome project, offer alternatives for in vivo protein synthesis regulation.
Area of Science:
- Biotechnology
- Genomics
- Pharmacology
Background:
- 34 protein-based biopharmaceuticals generated $10 million in sales in 1996.
- 200 out of 500 biopharmaceuticals in development are in clinical trials.
- Biologics face economic competition despite good efficacy and safety records.
Purpose of the Study:
- To explore the evolving landscape of biopharmaceutical therapies.
- To discuss the potential of gene therapy and oligonucleotide antisense therapy.
- To highlight the role of the human genome project in therapeutic development.
Main Methods:
- Analysis of market data for protein-based biopharmaceuticals.
- Review of biopharmaceutical development pipelines, including clinical trial status.
- Exploration of emerging therapeutic technologies and their supporting research.
Main Results:
- Protein-based biopharmaceuticals achieved significant market presence by 1996.
- A substantial number of biopharmaceuticals are progressing through clinical trials.
- Gene therapy and oligonucleotide antisense therapy are emerging as potential alternatives.
Conclusions:
- The human genome project will significantly influence the identification of new therapeutic targets at DNA, RNA, and protein levels.
- Future therapeutic strategies will integrate genomic insights for personalized medicine.
- The success of gene therapy versus small molecule screening will depend on genomic project outcomes and company research strategies.